Early Gene Testing to Guide Treatment in Hard-to-Treat Cancers
Compares early gene testing with later testing in adults with advanced cancers.
Plain-language title generated from the registry record
Registry title: Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers
Key facts
- Where
- Lille, FranceSee the site
Where in France
- Hôpital Claude Huriez - Service OncologieLille, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospital, Lille
- Trial code
- NCT06958224
- Record updated
- 22 October 2026
- Original description
The European Society for Medical Oncology (ESMO) strongly recommends to develop multigene sequencing in the framework of molecular screening programmes, in order to improve access to innovative drugs and to accelerate clinical research in cancers.Read full original descriptionShow less
Theranostic Approach by Early Multigene Sequencing in Advanced Poor Prognosis Cancers, Not Eligible for Initial Sequencing in Clinical Routine and Selected From the First Line in Molecular Tumour Board.
The European Society for Medical Oncology (ESMO) strongly recommends to develop multigene sequencing in the framework of molecular screening programmes, in order to improve access to innovative drugs and to accelerate clinical research in cancers.
* Accordingly, this project aims to study the contribution of early systematic multigene sequencing (NGS) discussed in Molecular Tumour Board for poor prognosis cancers, with no current indication for early sequencing. * The investigators teams propose to perform a randomized study in tumours in which actionable therapeutic targets according to the ESMO ESCAT scale are known (ESCAT II/IV) especially in pancreatic ductal adenocarcinoma, hepatocellular carcinoma or triple negative breast cancer.
Two approaches will be compared: a large multigenic early sequencing approach since the first line setting versus a Plan France Medecine Genomique 2025 approach since the second line setting.
The frequency of really initiated therapeutic proposals according to the molecular status will be compared in each group.
Inclusion: - Age >18 years; Advanced disease status ("unresectable" or "metastatic"); Patient included either at the time of diagnostic investigation or during first line of treatment; Good general conditions, still compatible with a therapeutic proposal, WHO 0-1; The following tumour sites, with poor prognosis and for which ESCAT II/IV treatment targets can be found according to ESMO:; pancreatic adenocarcinoma; hepatocellular carcinomas,; triple negative breast cancer; Tumour tissue a priori available in sufficient quantity: at least one biopsy from a visceral metastatic site or surgical specimen (if available) for eligible cancers; Patient covered by a social sercurity scheme.
Exclusion: - General condition WHO >1 and/or nutritional status not compatible with a therapeutic proposal; Active infection or active chronic disease (diabetes, liver dysfunction, immune disease) making the patient's condition incompatible with a therapeutic proposal; Limiting systemic cardiovascular, renal, bronchopulmonary or endocrinological comorbidities with the initiation of a therapeutic proposal; A priori unavailable, in insufficient quantity or of suboptimal quality tumour material; Administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of social security coverage, refusal to sign consent.